We are live on ! Find out more
MPM BioImpact

MPM BioImpact Portfolio holdings

AUM $1.35B Turnover 42.55%
1-Year Est. Return 172.14%
 

MPM BioImpact runs biotech venture, hybrid and hedge funds, and its impact funds put private and public money into companies aiming to change outcomes for patients with disease. Its hedge funds concentrate on small and mid-sized healthcare companies, while the firm as a whole combines MPM Capital's biotech venture capital record of more than 30 years with BioImpact's public investing. The firm was called MPM Oncology Impact Management until 2021 and BioImpact Capital until 2023. Ansbert Gadicke, its founder and managing partner, is also its controlling owner. Among its portfolio stories, it built the radiopharmaceutical company Aktis Oncology for solid tumors and was an early backer of argenx, an immunology company.

This Fund
S&P 500
This Quarter Est. Return
+42.6%
1 Year Est. Return
+172.14%
3 Year Est. Return
+619.29%
5 Year Est. Return
+756.25%
10 Year Est. Return
–
AUM
$376M
AUM Growth
+$212M
Cap. Flow
+$116M
Cap. Flow %
30.74%
Top 10 Hldgs %
99.83%
Holding
13
New
3
Increased
1
Reduced
–
Closed
2
Avg Time Held
0.3 years
Top 10 Avg Time Held
0.3 years
Top 20 Avg Time Held
0.3 years

Top Buys

Rank Stock Value
1
RPTX icon
Repare Therapeutics
RPTX
+$76.7M
2
ADCT icon
ADC Therapeutics
ADCT
+$20.5M
3
MRUS icon
Merus
MRUS
+$10.1M

Top Sells

Rank Stock Value
1
CTMX icon
CytomX Therapeutics
CTMX
+$6.56M
2
VIRX icon
Viracta Therapeutics
VIRX
+$1.17M

Sector Composition

Rank Sector Weight
1 Healthcare 88.87%
2 Miscellaneous 11.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
RPTX icon
1
DELISTED
Repare Therapeutics
RPTX
$74.1M 19.7%
+2,388,337
New +$76.7M
2020 Q2
0 quarters
HARP
2
DELISTED
Harpoon Therapeutics
HARP
$64.7M 17.21%
389,842
– –
2019 Q4
2 quarters
TCRR
3
DELISTED
TCR2 Therapeutics
TCRR
$51.8M 13.77%
3,370,982
– –
2019 Q4
2 quarters
EPZM
4
DELISTED
Epizyme
EPZM
$37.4M 9.96%
2,331,534
– –
2019 Q4
2 quarters
GTHX icon
5
DELISTED
G1 Therapeutics
GTHX
$34.5M 9.18%
1,423,794
– –
2019 Q4
2 quarters
ADCT icon
6
ADC Therapeutics
ADCT
$187M
$25.3M 6.72%
+539,648
New +$20.5M
2020 Q2
0 quarters
TPTX
7
DELISTED
Turning Point Therapeutics
TPTX
$19.9M 5.3%
308,686
– –
2020 Q1
1 quarter
YMAB icon
8
DELISTED
Y-mAbs Therapeutics
YMAB
$14.6M 3.87%
337,291
– –
2019 Q4
2 quarters
MRUS icon
9
DELISTED
Merus
MRUS
$11.3M 3%
+700,879
New +$10.1M
2020 Q2
0 quarters
AUTL icon
10
Autolus Therapeutics
AUTL
$303M
$637K 0.17%
39,740
– –
2019 Q4
2 quarters
CTMX icon
11
CytomX Therapeutics
CTMX
$436M
– –
-855,437
Closed -$6.56M –
VIRX icon
12
DELISTED
Viracta Therapeutics
VIRX
– –
-80,283
Closed -$1.17M –

Similar funds

MPM BioImpact's Q2 2020 Portfolio in Review

As of Q2 2020, MPM BioImpact held 13 positions worth $376M, up 130% from $164M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

MPM BioImpact deployed $116M of net new capital in Q2 2020, opening 3 new positions and adding to 1 existing holding. Its largest new stake was Repare Therapeutics: 2,388,337 shares worth $74.1M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 94% a quarter earlier, followed by Miscellaneous.

On the sell side, the most notable exit was CytomX Therapeutics, an estimated $6.56M sold.

  • MPM BioImpact's largest Q2 2020 buy was Repare Therapeutics: 2,388,337 shares worth $74.1M.
  • MPM BioImpact fully exited CytomX Therapeutics in Q2 2020, selling an estimated $6.56M.
  • MPM BioImpact's ten largest holdings make up 100% of its $376M portfolio in Q2 2020.
  • MPM BioImpact opened 3 new positions and closed 2 in Q2 2020.
  • MPM BioImpact's portfolio value rose 130% quarter-over-quarter to $376M.

Based on MPM BioImpact's 13F filing for Q2 2020, filed 12 Aug 2020.